Figure 2.
Proportion of patients (a) with presumed resistant hypertension and (b) without presumed resistant hypertension who achieved systolic blood pressure <130 mm Hg during the trial in empagliflozin and placebo groups.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.